Brief: Krystal Biotech Announces FDA Clearance Of Investigational New Drug Application For Kb408 For The Treatment Of Type 1 Alpha-1 Antitrypsin Deficiency
21/09/2023 14:23
Sept 21 (Reuters) - Krystal Biotech Inc KRYS.O :
* KRYSTAL BIOTECH ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR KB408 FOR THE TREATMENT OF TYPE 1 ALPHA-1
ANTITRYPSIN DEFICIENCY
* KRYSTAL BIOTECH INC - ANTICIPATES DOSING FIRST PATIENT IN
A
PHASE 1 CLINICAL TRIAL IN Q1 2024
Source text for Eikon: ID:nGNX81Zy0b
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Krystal Biotech
See all newsBrief: Krystal Biotech Announces Positive Clinical Data For New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression In Patients With Gorlin Syndrome
Krystal Biotech Inc reports results for the quarter ended June 30 - Earnings Summary
Krystal Biotech Q2 revenue rises on VYJUVEK strength
Brief: Krystal Biotech - Files Response With Uspto On Kb801 Patent Application - SEC Filing
Construction firm Tutor Perini jumps on S&P SmallCap inclusion